Cargando…
Considerations for routinely testing for high lipoprotein(a)
Lipoprotein (a) [Lp(a)] is a likely causal risk factor for atherosclerotic cardiovascular disease (ASCVD) and aortic valve disease, confirmed by Mendelian randomization. With reliable assays, it has been established that Lp(a) is linearly associated with ASCVD. Current low-density lipoprotein choles...
Autores principales: | Nurmohamed, Nick S, Moriarty, Patrick M, Stroes, Erik SG |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10328534/ https://www.ncbi.nlm.nih.gov/pubmed/35942815 http://dx.doi.org/10.1097/MOL.0000000000000838 |
Ejemplares similares
-
Lipoprotein(a), venous thromboembolism and COVID-19: A pilot study
por: Nurmohamed, Nick S., et al.
Publicado: (2022) -
Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement( )
por: Kronenberg, Florian, et al.
Publicado: (2022) -
Lipoprotein(a) and Its Potential Association with Thrombosis and Inflammation in COVID-19: a Testable Hypothesis
por: Moriarty, Patrick M., et al.
Publicado: (2020) -
Routine vaccination against MenB: Considerations for implementation
por: Kaaijk, Patricia, et al.
Publicado: (2014) -
Lp(a): a New Pathway to Target?
por: Nurmohamed, Nick S., et al.
Publicado: (2022)